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Abstract
Orthopaedic implant infections are an increasing problem and management commonly involves implant 
removal with serious consequences. Biofilm-forming staphylococci are the most common causative organisms, 
with Staphylococcus aureus being the most virulent and MRSA increasingly involved. Initial bacterial adhesion is 
a crucial event in biofilm formation and infection establishment. Directing host antibody against bacterial factors 
involved in adhesion and biofilm formation may significantly inhibit infection establishment on biomaterials. Two 
recombinant S. aureus-derived binding proteins (FnBP, IsdA) were investigated as potential vaccine antigens and 
resultant antibody was assessed to determine whether immune inhibition of bacteria-ligand binding can significantly 
impact on attachment to plasma-conditioned biomaterial surfaces, in the presence of other bacterial ligands.
Adhesion of homologous and heterologous (clinical MRSA) S. aureus to plasma-conditioned steel was 
significantly reduced (~50% average reduction, p<0.0001) when pre-exposed to anti-rFnBP-A antiserum that 
was 50-fold more dilute than the actual titre from immunisation. Inhibition was related to ligand presence and not 
staphylococcal Protein A. Reduced adhesion was not observed with an FnBP-mutant strain, indicating specific 
inhibitory antibody involvement, and demonstrating the potential of rFnBP-A for prevention of S. aureus implant-
related infection. Adhesion-inhibitory activity was also observed with a purified IgG-fraction of rIsdA antiserum but this 
activity appeared to be masked by non-IsdA–related interactions when non-IgG-purified antiserum was assessed.
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Introduction
Infections associated with implanted medical devices such as joint 
arthroplasty prostheses are an increasing problem due to mounting 
antibiotic resistance/insusceptibility of common causative organisms, 
and increased requirement by a more numerous ageing population. 
Antibiotics are crucial for prevention of infection during joint 
replacement implantation procedures [1]. Antibiotics are also the 
mainstay infection treatment option, in addition to debridement and 
removal of infected tissue and implanted biomaterials [1-3]. Prosthesis 
and tissue removal is the most common and typically only option for 
curing an infection, resulting in serious health, social and economic 
consequences (increased morbidity, mortality, prolonged hospital 
stay). The major source of intra-operative bacterial contamination 
in joint replacement surgery and other orthopaedic implant surgery 
is patient skin-derived bacteria [1,4]. Biofilm-forming staphylococci 
are the most common causative organisms, with Staphylococcus 
aureus being most virulent and responsible for approximately half 
the infections [4]. Staphylococcal resistance to antibiotics is mounting 
and increasingly Meticillin-Resistant S. aureus (MRSA) is involved in 
implant infections. The outcome of infection is significantly poorer 
if the causative organism is resistant to antibiotics [5-11] and MRSA 
more than doubles the infection mortality rate [5]. 
Bacterial biofilm formation during infection establishment also 
leads to reduced susceptibility of quiescent cells embedded within 
the biofilm and antibiotic treatment failure [12,13]. Insusceptibility 
to combined antibiotics [14], bacterial persistence in the face of an 
immune response [15], and enhanced transfer of resistance elements 
[16] are also key problems associated with biofilm infection. Initial 
bacterial adhesion to the host plasma-conditioned prosthesis and 
surrounding tissue mediated by bacterial-binding proteins is a primary 
event in biofilm formation [17-19], followed by intercellular adhesion 
and formation of multi-cellular layers (biofilm) [15]. Although bacteria 
can establish infection at the implant surface and in the peri-implant 
tissue, there is evidence to suggest that bacteria at the implant surface 
may be more important for infection persistence and worse outcome 
for the patient [20]. Binding of S. aureus to plasma glycoproteins (Fg-
fibrinogen, Fn-fibronectin) that coat implanted biomaterial (and aid 
binding to tissues) is important in initiation of biomaterial-related 
infection [17-19], and the two most potent S. aureus binding proteins 
that have been shown to be important for this interaction are the 
fibronectin-binding protein (FnBP) and fibrinogen-binding iron-
surface determinant (IsdA).
Binding to fibronectin appears to be an extremely important 
mechanism during S. aureus infection, evidenced by the duplicity of 
binding protein expression (FnBP-A, FnBP-B), the multiplicity of Fn-
binding domains and functions of each protein [21-26]. Almost all 
clinical isolates express the FnBP’s singly or in combination [27,28], 
FnBP-A is expressed by all of the most prevalent epidemic MRSA 
(EMRSA) clones in the UK [29-31] and prevalence of the fnb genes 
is extremely high among orthopaedic isolates (99% of 191 isolates) 
[28]. Fusion proteins comprising the β–galactosidase gene from E. 
Citation: Ratcliffe E (2014) Staphylococcus aureus Binding Proteins for Prevention of Orthopaedic Implant-Related Infections. J Microb Biochem 
Technol 6: 303-313. doi:10.4172/1948-5948.1000160
Volume 6(5): 303-313 (2014) - 304J Microb Biochem Technol        ISSN: 1948-5948 JMBT, an open access journal
coli and full-length FnBP-A, truncated binding-domain sequences 
(D-domain), or complete recombinant FnBP-A have demonstrated 
partial protection as immunogens in animal models of endocarditis 
and mastitis infections [32,33]. Fibrinogen binding is also extremely 
important for infection establishment and of the fibrinogen-binding 
proteins expressed by S. aureus, Clumping factor A (ClfA) is considered 
of premier importance and best characterised. However, the heme-
scavenging broad spectrum adhesin termed the iron-regulated surface 
determinant protein A (IsdA) was previously shown to bind fibrinogen 
and fibronectin under iron-limited conditions in-vitro, with its affinity 
for fibrinogen being 20-fold higher than that determined for the 
ClfA binding domain [34]. Evidence suggests that IsdA has multiple 
functions and plays a role in iron-acquisition [35,36], it is also known 
to be expressed during growth in human serum [37] and screening of 
serum samples from patients convalescing from S. aureus infections 
demonstrated the expression of IsdA during infection [34]. IsdA has 
been investigated as a vaccine antigen to prevent haematogenous S. 
aureus infection and lethal challenge [38,39] was also recently shown to 
be important for nasal carriage as vaccination with recombinant IsdA 
significantly reduced S. aureus nasal carriage in cotton rats [40]. 
Pre-operative vaccination in elective orthopaedic cases could be a 
viable alternative approach for prevention of infection to reduce both 
infection rate and severity. There are increasing requirements to develop 
complimentary preventive strategies without giving rise to antibiotic 
resistance or undesirable implant/fixative effects on integration. A 
vaccine against staphylococcal biomaterial-related infection will likely 
target multiple surface expressed virulence factors from S. aureus 
and S. epidermidis (significant causative organism) that are crucial to 
bacterial adherence and biofilm formation. This paper describes the 
in vitro investigations of two potential S. aureus vaccine candidates to 
determine whether antibody directed against staphylococcal binding 
protein is capable of inhibiting bacterial attachment to plasma-
conditioned biomaterials. 
Methods
Bacterial strains, plasmids, sequences and culture conditions
Table 1 lists the bacterial strains used in this study. Staphylococcal 
strains were routinely cultured aerobically at 37°C on Blood agar base 
No. 2 with sheep blood or Tryptic Soy Agar (TSA). Aerobic 37°C broth 
cultures used Tryptic Soy Broth (TSB) (Oxoid, Basingstoke, UK) or 
Chemically Defined Metal Limitation (CL) medium [41] with 200 rpm 
aeration, and supplemented with 5 µg ml-1 erythromycin, tetracycline, 
or 1 µM ml-1 ferric chloride (FeCl3) where appropriate (Sigma-Aldrich 
Ltd., Dorset, UK). Strains were characterized using standard techniques 
including antibiogram and API Staph, and expression/non-expression 
of target protein was confirmed by western immunoblotting analysis. 
E. coli strains were routinely cultured aerobically on Luria-Bertani 
(LB) agar, or medium [42] with 250 rpm aeration, and supplemented 
with 100 µg ml-1 ampicillin or 50 µg ml-1 kanamycin where appropriate 
(Sigma). Bacterial growth was monitored by absorbance at 600 nm 
for E. coli cultures and 490 nm for staphylococcal cultures using an 
Ultraspec 2000 spectrophotometer (Pharmacia Biotech, Cambridge, 
UK).
The amino acid sequence and organization of the FnBP-A protein 
from S. aureus 8325-4 is shown in Figure 1, where the purified domain 
is highlighted. Although our interest lies in the knowledge that IsdA is 
a potent fibrinogen binding protein, we were also interested in IsdA as 
a general adhesin capable of binding multiple ligands potentially in the 
establishment of orthopaedic implant infections. Therefore full length 
IsdA rather than the NEAT domain was used in this study (Figure 2).
Bacterial cell clumping assay
To confirm IsdA expression during culture of S. aureus SH1000 
under conditions appropriate for the adhesion assays, the ability of cell-
surface exposed IsdA to enhance bacterial cell clumping in the presence 
of fibrinogen was assessed for S. aureus SH1000 after being cultured 
to stationary phase (24 h) in iron-depleted and iron-replenished (20 
µM FeCl3) CL medium and compared to that of S. aureus SRC005 
(isdAˉ) using a method previously described [21,34]. Standardized 
bacterial suspensions (107 CFU ml-1) were concentrated to one fifth of 
the original culture volume in sterile PBS and each concentration was 
exposed to serial two-fold dilutions of (fibronectin-depleted) human 
fibrinogen (2 mg mL-1 serially diluted in sterile PBS). Samples were 
agitated at 200 rpm for 5 minutes at room temperature and visually 
examined for bacterial clumping using a light microscope. Clumping 
titers were recorded as the lowest fibrinogen concentration at which 
clumping remained visible.
Recombinant protein production
Presence of target staphylococcal sequences in E. coli expression 
plasmids were confirmed using automated dye-terminator sequencing 
(Sequencing Unit, University of Nottingham, UK). Recombinant 
protein expression from pQE vector constructs or pET24d vector 
constructs was performed according to vector manufacturer’s 
instructions (Qiagen or Novagen respectively). In brief, overnight 
E. coli cultures in LB medium with supplemented antibiotics were 
diluted 1:20 or 1:25 respectively using fresh medium and cultured 
until an A600 of 0.6 was achieved. Recombinant protein expression 
was induced by addition of 0.25 or 0.1 mM IPTG respectively (Sigma) 
with further culture for 3-4 h. Expression cultures were analyzed by 
Strain Properties
Staphylococcus aureus
8325-4a Wild type strain (rsbU - mutant) expressing FnBP-A, FnBP-B. NCTC 8325 cured of prophages [43].
DU5883a FnBP-A, FnBP-B –deficient mutant of 8325-4 (fnbA::tet fnbB::ery) [44]. Tetracycline and Erythromycin resistance.
DU5723a Protein-A –deficient mutant of 8325-4 (Δspa-600::EtBr) [45].
MRSAb Clinical Meticillin resistant S. aureus arthroplasty isolate. 
SH1000c Wild type 8325-4 derivative strain expressing IsdA (rsbU+) [46].
SRC005c IsdA-deficient mutant of SH1000 (isdA::Tn917 ery) [40]. Erythromycin resistance.
Escherichia coli
514a E. coli XL1-Blue RecAˉ harbouring plasmid pQE30–fnbA D1-4 [47,48]. Ampicillin resistance. 
BL21 (DE3) pSRC00c E. coli BL21 (DE3) harbouring plasmid pET24d–isdA [40]. Kanamycin resistance. 
aStrains donated by Professor T. Foster, Trinity College, Dublin, Ireland. Cloning of fnbA D1-4 has been previously described [47,48]. bStrains donated by Southport and 
Ormskirk Hospital, Merseyside, UK. cStrains donated by Professor S. Foster, University of Sheffield, UK. Cloning of isdA has been previously described [40]. 
Table 1: Bacterial strains.
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SDS PAGE and western transfer [42] with chemiluminescent detection 
of His6-tagged recombinant protein using anti-his tag monoclonal 
mouse antibody (Novagen; Merck Chemicals Ltd., Nottingham, UK), 
goat anti-mouse immunoglobulin horseradish peroxidase-conjugated 
antibody (Sigma) and the Amersham ECL western blotting detection 
system (GE Healthcare Ltd., Buckinghamshire, UK). 
Recombinant protein purification was performed by metal 
chelate affinity chromatography using the His-BindTM purification 
kit according to manufacturer’s instructions (Novagen), and 
chromatography samples were analysed by SDS PAGE and 
chemiluminescent western immunoblotting as before. Elutions were 
concentrated using Centriprep centrifugal filter units (Millipore, 
Watford, UK) and dialysed into sterile phosphate buffered saline (PBS) 
(Oxoid) using a Slide-A-Lyzer dialysis cassette (ThermoScientific, 
Rockford, USA). Recombinant protein concentration was determined 
using the BioRad protein concentration assay (BioRad Laboratories 
Ltd., Hemel Hempstead, UK). 
Functional ligand-binding of recombinant proteins was determined 
by ELISA [42] using 5 µg ml-1 of purified human fibronectin, fibrinogen 
or bovine serum albumin (BSA) solubilised in sterile PBS for coating 
of microtitre plate wells (Corning Inc., New York, USA). A 5% w/v 
BSA in PBS blocking solution was used and bound His6-tagged 
recombinant protein was detected using anti-his tag mouse antibody, 
alkaline phosphatase-conjugated goat anti-mouse antibody (Sigma), 
and alkaline phosphatase p-nitrophenyl substrate (Sigma). Absorbance 
was read at 405 nm (A405) in a BioTek EL800 plate reader (BioTek 
Instruments Inc., Vermont, USA).
Antiserum production
Antiserum production was outsourced and performed by 
Eurogentec Ltd. (Seraing, Belgium) using a standard polyclonal 
antibody programme. The programme used by Eurogentec Ltd. 
briefly comprises immunisation of two adult (specific pathogen free) 
New Zealand White rabbits with 100 µg of purified recombinant 
protein antigen emulsified in complete Freund’s adjuvant, followed 
by three booster immunizations in incomplete Freund’s adjuvant 
over eight weeks. Prior to primary immunization and throughout 
the immunization schedule, sample bleeds were harvested from both 
rabbits using sterile Vacutainer®-tubes (Table 2 shows the immunization 
and bleed schedule). A fraction of the final bleed antiserum from one 
of the immunised rabbits (randomly selected) was IgG-purified on a 
Staphylococcus aureus Protein G column (Pharmacia), and analysed for 
purity and concentration by SDS PAGE. Serum titer of antigen-specific 
antibody was performed by ELISA as described previously using 5 µg 
ml-1 of purified recombinant protein or BSA, BSA blocking solution 
and application of two-fold serial dilutions of rabbit antiserum in sterile 
PBS containing 0.1% w/v BSA [43]. Bound antibody was detected as 
described previously using alkaline phosphatase-conjugated goat anti-
rabbit antibody (Sigma).
ATP bioluminescent adhesion assay 
A static adherence test was selected to assess adherence inhibition 
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Figure 1: rFnBP-A D1-4 ligand-binding and serum titre ELISA’s. A: increasing 
concentrations of purified rFnBP-A D1-4 were exposed to BSA (closed 
symbols) or human fibronectin (open symbols) -coated wells and detected 
using the p-nitrophenyl phosphate system from Sigma. B: Serum titre ELISA 
using rFnBP-ABCD476-838 (open symbols) and BSA (closed symbols) 
-coated wells exposed to two fold serial dilutions of rabbit pre-immune serum 
(diamond symbols), rFnBP D1-4 post-immune serum (square symbols), and 
an IgG purified fraction of post-immune serum (triangle symbols). All assays 
were performed in triplicate and values represent the mean absorbance at 
405 nm (A405) with the standard error (error bars are shown in black on all 
graphs, but are difficult to see in some cases on account of the errors being 
small).
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Figure 2: S. aureus SH1000 IsdA amino acid sequence and schematic 
organisation. NEAT domain highlighted in light blue, the LPXTG (LPKTG) 
motif is shown in italic type and underlined in black. The translational start (M) 
and stop codons (*) are also shown. The amplified domain is highlighted by 
red lines on the schematic representation and red underlining on the amino 
acid sequence. Sequence was adapted from Taylor and Heinrichs, 2002, 
NCBI Accession number AY061874.
Day Immunisation Sample bleed
0 Primary (100 µg, CFA) Pre-immune (2 mL)
14 Booster 1 (100 µg, IFA)  
28 Booster 2 (100 µg, IFA)  
38  Small test bleed (2 mL)
56 Booster 3 (100 µg, IFA)  
66  Large test bleed (20 mL)
87  Final bleed (50-70 mL)
Table 2: Standard polyclonal antiserum production schedule.
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Each matrix was repeated in triplicate using fresh bacterial cultures for 
each experiment. Replicate RLU data from the triplicate matrix assays 
was pooled (n>100 per parameter) and converted into % average 
adherent CFU ml-1. 
Statistical analysis
All un-paired continuous data was displayed as the mean and 
standard error of the mean. The un-paired t-test (two tailed) was used 
for comparison of data means and was adjusted for equal or unequal 
variance using the F-test, a 5% significance level was adopted (p<0.05), 
and where statistical analysis of small sample size data is described, 
the actual sample size is stated in the text. Where discrete data was 
obtained and displayed using the sample median and inter-quartile 
range, the Mann Whitney U-test was used for statistical comparison 
of sample medians, and a 5% significance level was adopted (p<0.05).
Results and Discussion
rFnBP-A functional ligand and serum titer
Functional ligand binding of E. coli-expressed soluble rFnBP-A 
(D1-4) binding domain was assessed by ELISA prior to antiserum 
production. Statistically significant and specific ligand binding was 
observed upon exposure to fibronectin (Figure 1A, p<0.001, n=9). 
Significant increases in fibronectin binding were observed with 
increasing rFnBP-A D1-4 concentrations (p<0.05, n=9). Strong 
specific antibody responses were also observed (Figures 3A and 3B) 
with both the un-purified and IgG-purified post-immune serum 
against immobilised rFnBP-A, compared to that observed with serum 
collected from rabbits before immunisation (pre-immune serum), and 
compared to exposure to immobilized BSA (p<0.0001, unpaired t-test, 
n=4 per parameter, all tested dilutions). The cut-off was determined as 
A405 0.19 (μ+2σ) and the endpoint dilution determined as 102,400. A 
working titer of 1000 was adopted for adhesion assays. Although one 
would expect some loss of IgG during purification, significant loss was 
not observed (as evidence by the ELISA) and an equivalent dilution was 
determined as the appropriate working titer for comparison.
The staphylococcal strains selected for biomaterial adhesion assay 
analysis of rFnBP-A D1-4 antiserum were the homologous S. aureus 
8325-4 strain (derived antigen sequence) and two S. aureus 8325-4 
mutant strains; S. aureus DU5883 which is deficient in FnBP(-A,-B) 
expression; and DU5723 which is deficient in Protein-A expression. 
Additionally, a heterologous clinical MRSA arthroplasty isolate was 
also selected. Strain validation tests performed prior to adhesion 
in the presence of other ligands without introducing shear stress and 
minimizing opportunity for variability, a static test is suitable for initial 
studies as there is negligible shear at the bone-implant interface. Use 
of ATP as a biochemical marker for quantifying bacterial adherence 
to biomaterial surfaces was previously shown to be comparable to 
conventional methods for viable count determination [32-34]. Prior to 
adhesion assays, FnBP expression under appropriate culture conditions 
was confirmed by SDS PAGE and western transfer analysis, and IsdA 
expression under appropriate culture conditions was confirmed using a 
bacterial cell clumping assay to assess the ability of IsdA to enhance cell 
clumping in the presence of fibrinogen after culture in iron-depleted or 
iron-replete CL medium [21,34].
Standardized exponential phase staphylococcal suspensions (107 
CFU ml-1) in sterile distilled water with 2% v/v fresh culture medium 
were prepared and split into four 9.8 mL aliquots. Table 3 shows 
the experimental condition matrix for this study. Test aliquots were 
supplemented with pre-immunized, post-immunized or IgG-purified 
post-immunized rabbit serum at working antibody titer of 1000 or 
the equivalent volume of control serum or sterile distilled water. 
Suspensions were incubated at 37°C with 50 rpm shaking for 1 h for 
antibody exposure. Suspensions were then aliquoted (18×0.5 ml) for 
biomaterial exposure to unconditioned medical grade stainless steel 
coupons (5 mm width, 5 mm length, 0.25 mm thickness) (Goodfellow, 
Huntingdon, UK) or coupons that had been pre-conditioned with 
pooled normal (non-immunized) rabbit plasma (Cambridge Bioscience 
Ltd, Cambridge, UK) (9×0.5 ml each). Exposure was carried out for 1 
h at 37°C, and coupons were aseptically removed and rinsed prior to 
bacterial quantification. Adherent bacteria were removed by sonication 
at 50-60 Hz for 20 minutes (Ultrawave Ltd., Cardiff, UK) and 100 µl of 
sonicate suspensions were applied in triplicate to wells of an opaque 
96-well culture plate (Zeptogen Ltd., Middlesex, UK). Cells were lysed 
by addition of 100 µL of Bactolyse (Cambrex, Rockland, USA) and ATP 
release was detected in a Microlumat plus LB 96 V luminometer at 595 
nm (Berthold Technologies, Redbourn, UK). Triplicate bacterial lawns 
were also prepared from sonicate suspensions for semi-quantitative 
confirmation of the relative light unit (RLU) measurements [44,45]. 
Standard curves of ATP bioluminescence and viable cell numbers 
were produced for each bacterial strain cultured under standardized 
conditions to enable accurate conversion of RLU measurements into 
bacterial colony forming units (CFU, data not shown). The adhesion 
assay matrix was performed using a single standardized bacterial 
culture for each strain to be tested, such that the same population of 
bacterial cells was exposed to the different parameters or immune sera. 
B
iom
aterial
Serum None (distilled water control) Pre-immune serum Post-Immune serum IgG-purified serum
Stainless Steel n=9* n=9 n=9 n=9
Plasma-conditioned Stainless Steel n=9 n=9 n=9 n=9
*n=number of individual test reactions, quadruplicate RLU measurements were taken of individual test reactions, thus n=36 for RLU measurements.
**Condition matrix repeated in triplicate (separate experiments) for each test antigen and appropriate bacterial strain. 
Table 3: Experimental Condition Matrix**.
Medium S. aureus strain Dilution factor Average RLU Amount of ATP Average CFU ATP per RLU ATP per CFU
TSB
8325-4 41686 136.5 9.9635-7 312 7.2993-9 3.1934-9
DU5883 41686 138.25 1.01095-6 310 7.3125-9 3.2611-9
DU5723 41686 136.5 9.9635-7 312 7.2993-9 3.1934-9
MRSA 41687 131.25 9.5803-7 263 7.2993-9 3.6427-9
CL SH1000 41687 67 4.8905
-7 237 7.2993-9 2.0635-9
SRC005 41686 78.41 5.7234-7 301 7.2993-9 1.9015-9
Table 4: Value table and calculation for average cellular ATP concentration.
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assays included confirmation of bacterial strain properties (expression 
or non-expression of FnBP); confirmation of expression throughout 
the bacterial growth phase and during adherence assay culture; 
determination of cellular ATP levels for each strain; and validation 
of adhesion assay sensitivity under standardized conditions (Table 
4, Figures 4A and 4B). Assay sensitivity for the desired application 
was determined as minimum RLU detection at 595 nm of 150, which 
equates to 5×102 CFU. 
To convert RLU (595 nm) to CFU ml-1:
CFU ml-1 = 10×[RLU×(ATP per RLU)/(ATP per CFU)]
rFnBP-An antibody inhibition of bacterial binding
Figure 5 shows the adherence assay results for S. aureus DU5883 
(FnBP mutant), 8325-4 (homologous), DU5723 (Protein A mutant), 
and the MRSA arthroplasty isolate after exposure to antiserum (raised 
against rFnBP-A D1-4) and plasma-conditioned steel coupons. 
Bacterial adherence to a plasma-conditioning film without inhibitory 
antiserum exposure was significantly greater (p<0.001, Figure 5A) with 
FnBP-expressing strains compared to S. aureus DU5883, thus further 
demonstrating the importance of fibronectin-binding via FnBP.
Exposure to pre-immune serum significantly promoted the 
adhesion of all bacterial strains above the levels observed without 
antiserum exposure (p<0.003, Figure 5A), but for S. aureus DU5883 this 
promoted adherence remained significantly lower than that observed 
for strains expressing FnBP (p<0.0001, Figure 5A). This promotion 
of adhesion through pre-exposure to serum protein is likely mediated 
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Figure 3: rFnBP-A D1-4 ligand-binding and serum titre ELISA’s.
A: increasing concentrations of purified rFnBP-A D1-4 were exposed to 
BSA (closed symbols) or human fibronectin (open symbols) -coated wells 
and detected using the p-nitrophenyl phosphate system from Sigma. B: 
Serum titre ELISA using rFnBP-A BCD476-838 (open symbols) and BSA 
(closed symbols) -coated wells exposed to two-fold serial dilutions of rabbit 
pre-immune serum (diamond symbols), rFnBP D1-4 post-immune serum 
(square symbols), and an IgG purified fraction of post-immune serum (triangle 
symbols). All assays were performed in triplicate and values represent the 
mean absorbance at 405 nm (A405) with the standard error (error bars are 
shown in black on all graphs, but are difficult to see in some cases on account 
of the errors being small).
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Figure 4: Standard Curves.
A. Replication phase standard curves. S. aureus 8325-4, DU5883, DU5723, 
and the MRSA arthroplasty isolate cultured in TSB with incorporated 
tetracycline and erythromycin for S. aureus DU5883. Assays were performed 
in triplicate and the mean absorbance at 490 nm (A490) with the standard 
error was plotted against culture time. B. Viable cell number standard curves. 
Cell density (CFU) and ATP-bioluminescence emitted from serially diluted 
standardised cultures of S. aureus 8325-4, DU5883, DU5723 (B1) and the 
MRSA arthroplasty isolate (B2) cultured in TSB with incorporated tetracycline 
and erythromycin for S. aureus DU5883. Assays were performed in triplicate 
and the mean relative light units (RLU) at 595nm (A595) with standard error 
was plotted against average CFU (error bars are shown in black on all graphs, 
but are difficult to see in some cases on account of the errors being small).
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through staphylococcal surface protein interaction, in part via FnBP 
(evidenced by the reduction observed with the mutant strain), but 
also through non-FnBP interactions such as clumping factor binding 
of fibrinogen and fibronectin, Protein A interactions as well as non-
specific interactions. 
Post-immune serum exposure significantly reduced adhesion 
of both the homologous S. aureus 8325-4 and heterologous MRSA 
arthroplasty isolate when compared to pre-immune serum exposure 
(−26.5% p<0.0007, −54.5% p<0.0001 respectively, Figure 5B), whereas 
adhesion of S. aureus DU5883 was significantly enhanced by exposure 
to post-immune serum (+50.3% p<0.0001, Figure 5B). Promotion of S. 
aureus DU5883 adherence above the level observed with pre-immune 
serum does not involve FnBP but may be related to immunisation 
and other unknown alterations this has caused. The opposite results 
of significantly reduced and significantly promoted adhesion after 
exposure to post-immune serum observed with S. aureus 8325-4 and 
DU5883 respectively, suggests that the reduced adhesion observed for 
S. aureus 8325-4 is related to reduced fibronectin-binding capacity and 
possibly the presence of adhesion-inhibitory rFnBP-A (D-domain) 
antibody. 
To clarify whether the results observed with post-immune serum 
were IgG-related the adherence assay was also performed after 
exposure to purified IgG from a fraction of the post-immune serum. 
Equivalent levels of adhesion to that observed with un-purified post-
immune serum were observed with the purified IgG fraction for all 
three strains (8325-4; −54.8% p <0.0001, MRSA; −47.4% p<0.0001, 
DU5883; +35.5% p<0.0004, compared to pre-immune serum exposure, 
Figure 5B). This suggests that the reduced adhesion observed with S. 
aureus 8325-4 and the MRSA arthroplasty isolate is in part related to 
adhesion-inhibitory IgG interactions resulting from immunisation 
with rFnBP-A (D1-4). The fact that a further significant reduction in 
adhesion to plasma-conditioned steel was observed for S. aureus 8325-4 
after exposure to purified IgG compared to whole post-immune serum 
supports this result (−28.3% p=0.004). A significant effect on adhesion 
of S. aureus DU5883 after exposure to purified IgG compared to un-
purified post-immune serum was not observed. Instead an equivalent 
level of significant adhesion-enhancement was observed. Thus further 
supporting the theory that adhesion-inhibitory rFnBP-A (D-domain) 
antibody is responsible for the reduced adhesion observed with FnBP-
expressing strains, and that the adhesion promotion observed with S. 
aureus DU5883 is partly due to non-specific IgG interactions. 
The significant reductions in staphylococcal adhesion to plasma-
conditioned steel observed after exposure to hyperimmune serum were 
not observed on adhesion to un-conditioned steel, and in fact opposite 
results were observed. Adhesion of S. aureus 8325-4 to un-conditioned 
steel was significantly promoted to equivalent levels after exposure 
to un-purified and IgG purified post-immune serum compared to 
the level of adhesion observed after exposure to pre-immune serum 
(+28.4% p=0.01, +48.5% p<0.0001 respectively, Figure 5C). In addition 
to this, adhesion of S. aureus DU5883 to un-conditioned steel was also 
significantly promoted above the levels observed with pre-immune 
serum exposure, after exposure to un-purified and IgG-purified post-
immune serum (+66% p<0.0001, +17% p=0.053 respectively, Figure 
5C). These results confirm that the significantly reduced adhesion of 
homologous S. aureus 8325-4 after exposure to rFnBP-A D1-4 post-
immune serum (un-purified and IgG-purified) in the presence of a 
plasma-conditioning film is specifically related to adhesion-inhibitory 
IgG interactions resulting from immunization with rFnBP-A D1-4 and 
the presence of the plasma glycoprotein conditioning film, of which 
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Figure 5: Adhesion assays with rFnBP-A D1-4 antiserum.
A. Adherence of standardised cultures of S. aureus 8325-4, DU5883 (FnBP-
A/B-deficient mutant), DU5723 (Protein A-deficient mutant), and MRSA 
to rabbit plasma-conditioned stainless steel coupons, with or without prior 
antiserum exposure (working titre of 1000, controls sterile deionised H2O). 
B. Normalised mean adherence change expressed as a percentage of the 
adherence in presence of pre-immune serum to plasma-conditioned or un-
conditioned stainless steel coupons for S. aureus 8325-4, DU5883 and 
MRSA with exposure to rFnBP-A post-immune or purified IgG post-immune 
serum. All results were statistically significantly different to pre-immune serum 
exposure. C. Normalised mean adherence change expressed as a percentage 
of the adherence in presence of pre-immune serum to plasma-conditioned 
stainless steel coupons for S. aureus 8325-4 and DU5723 with exposure to 
rFnBP-A post-immune, rFnBP-A purified IgG post-immune serum or control 
purified IgG serum (*denotes a statistically significant p<0.05 difference to 
pre-immune serum exposure).
In all cases adherence was quantified by ATP-bioluminescence and culture. 
Assays were performed in triplicate and values represent the mean adherent 
CFU ml-1 or mean % adherent CFU ml-1 with standard error of pooled data 
(n>100 per parameter, error bars are shown in black). Sample means were 
compared by un-paired t-test adjusted for equal or unequal sample variances, 
significance level was p<0.05.
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fibronectin is a major constituent, thus further supporting the presence 
of adhesion-inhibitory rFnBP-A-specific antibody. 
As staphylococcal Protein A binds host IgG by the Fc region, 
effectively coating the bacterial cell with host antibody in the wrong 
orientation for signalling host immune responses, it is logical to 
suggest that pre-incubating bacterial cells with antiserum could lead 
to some of the effects observed in the adherence tests being related 
to Protein A interactions. Therefore involvement of Protein A was 
investigated using a Protein A mutant derivative of S. aureus 8325-4. 
Adhesion of S. aureus DU5723 to plasma-conditioned steel was almost 
identical to that observed for S. aureus 8325-4 for each parameter 
tested, with significant promotion after pre-immune serum exposure 
(+75%, p<0.0001, Fig 5A) and significant (non-Protein A mediated) 
inhibition after exposure to rFnBP-A-immunised purified IgG (-39.9%, 
p<0.0001, Figure 5C). Reduced adhesion was observed after exposure 
to un-purified post-immune serum, but the levels were not as great as 
those observed with S. aureus 8325-4 and did not achieve statistical 
significance (−12.1% p=0.07, Figure 5C). In fact, the difference in the 
level of adhesion observed after exposure to un-purified post-immune 
serum between the two strains was near-significant statistically 
(p=0.052, Figure 5C). Purified IgG from sham immunized rabbits 
acted as a control to determine whether any other constituent of the 
purified IgG from immunized rabbits was responsible for the adhesion-
inhibitory effects observed. Adhesion after exposure to the purified 
IgG sham control was equivalent for both strains and no statistical 
difference was observed (Figure 5C). 
Taken together, and since significant inhibition was not observed 
with either strain and exposure to sham control IgG, the results suggest 
that inhibition of adhesion with purified IgG from a rabbit that was 
immunized with rFnBP-A D1-4 is specifically related to immunization 
and the interaction between generated antibody and staphylococcal 
FnBP-A. The near significant un-purified post-immune serum results 
suggest some possible involvement of protein A in the complete test 
system. However in the more specific test system using rFnBP-A- 
immunized and sham control IgG fractions, the presence or absence 
of Protein A had negligible effect on the adhesion levels observed after 
exposure to either of these fractions. Significant inhibitory activity 
was observed with the immunized IgG fraction whereas no significant 
difference in adhesion was observed with the sham control IgG fraction, 
suggesting no involvement of Protein A–IgG specific interactions. 
Speculatively, it is possible that an unknown direct or indirect Protein 
A interaction with other constituents of the un-purified post-immune 
serum may be enhancing the adhesion-inhibitory activity observed 
with the non-mutant strain (8325-4).
rIsdA functional ligand, serum titer and bacterial expression 
Statistically significant and specific functional ligand binding 
was observed upon exposure of purified rIsdA to fibrinogen (Figure 
6A, p<0.001, n=9). Significant increases in fibrinogen binding were 
observed with increasing rIsdA concentrations (p<0.001, n=9). 
Hyperimmune serum showed strong specific responses against 
immobilised rIsdA, compared to pre-immune serum and exposure to 
immobilized BSA at all antibody dilutions tested (p<0.0001, unpaired 
t-test, n=4 per parameter, Figure 6B). The cut-off was determined as 
A405 0.16 (μ+2σ) and the endpoint dilution determined as 102,400 
(purified IgG titer was not significantly different). A working titer of 
1000 was adopted for adhesion assays. 
The staphylococcal strains selected for biomaterial adhesion assay 
analysis of rIsdA antiserum were the homologous S. aureus SH1000 
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Figure 6: rIsdA ligand-binding and serum titre ELISA’s.
A: increasing concentrations of purified rIsdA were exposed to BSA (closed 
symbols) or human fibrinogen (open symbols) -coated wells and detected 
using the p-nitrophenyl phosphate system from Sigma. B: Serum titre ELISA 
using rIsdA (open symbols) and BSA (closed symbols) -coated wells exposed 
to two-fold serial dilutions of rabbit pre-immune serum (diamond symbols), 
rIsdA post-immune serum (square symbols), and an IgG purified fraction of 
post-immune serum (triangle symbols). All assays were performed in triplicate 
and values represent the mean absorbance at 405 nm (A405) with the 
standard error (error bars are shown in black on all graphs, but are difficult 
to see in some cases on account of the errors being small). Image C shows 
specific rIsdA detection by western immunoblotting using rIsdA post-immune 
serum and the purified IgG fraction (IgG) compared to the rabbit pre-immune 
serum (Pre). M represents the SDS PAGE (low range) molecular weight 
marker from BioRad.
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strain (8325-4 derivative strain, derived antigen sequence) and the 
derived mutant strain S. aureus SRC005 which is IsdA-deficient 
(Figure 6C). Prior to performing the adherence tests, the same series 
of validation assays were performed as described for rFnBP-A, with 
an additional validation assays to determine growth and expression of 
IsdA under iron-limiting conditions. 
Optimal expression of IsdA by S. aureus SH1000 was previously 
shown after 18 h of culture into stationary phase in iron-limited medium 
(CL medium) that was representative of in-vivo conditions [34]. Under 
these in vitro iron-limiting conditions, the fibrinogen clumping titre 
of S. aureus increases when IsdA is expressed on the cell surface [34]. 
Bacterial cell clumping was assessed for S. aureus SH1000 after being 
cultured to stationary phase in iron-depleted and iron-replenished CL 
medium and compared to that of S. aureus SRC005 (isdAˉ) using a 
method previously described (Figure 7A) [21,34]. Visual examples of 
bacterial clumping in decreasing fibrinogen concentrations and the PBS 
control are also shown (Figure 7B). Culture in iron-limited CL medium 
significantly promoted the cell clumping ability of S. aureus SH1000 
in the presence of fibrinogen (median titer 3.91 µg ml-1) compared to 
culture in iron-replenished CL medium (7.81 µg ml-1), and compared 
to the cell clumping ability of S. aureus SRC005 in either CL (7.81 µg 
m-1) or CL FeCl3 medium (7.81 µg m-1) (p<0.02, Mann-Whitney U 
test, n=7 per parameter). Similar clumping titers were observed for 
S. aureus SH1000 and SRC005 after culture in iron-replete medium, 
which differ only in their ability to express IsdA. Enhanced clumping 
was observed with S. aureus SH1000 under iron-limited conditions 
only. Taken together the data suggest that the significant promotion of 
cell-mediated clumping in the presence of fibrinogen above the levels 
observed where other proteins such as clumping factors (ClfA, ClfB) 
are primarily responsible is directly related to optimal expression of 
IsdA. The data also suggest that 1 µM ml-1 iron chloride is sufficient for 
repression of IsdA expression equivalent to that of a non-expressing 
mutant strain, as previously demonstrated for IsdB [46-49]. 
Replication phase and viable cell number standard curves were 
produced for S. aureus SH1000 and SRC005 when cultured in CL, CL 
FeCl3 and TSB medium (Figure 8A). As optimal expression of IsdA was 
shown previously after 18 h culture in CL medium, this same culture 
time was adopted for the adherence tests. There was no difference in 
bacterial cell density when strains were cultured in CL or CL FeCl3 
medium. However, cell density was significantly reduced for both 
strains in either of these media when compared to standard culture 
in TSB medium (p<0.05, unpaired t-tests, n=3 per parameter, all time 
points, Figure 8B). Previous research has shown that S. aureus SH1000 
exhibits a decreased lag phase before exponential growth [46] and 
an increased growth yield compared to S. aureus 8325-446, [50] and 
these differences along with production of staphyloxanthin (orange 
pigment) [41] were also observed in this study (data not shown). S. 
aureus SH1000 has a functional rsbU and restored σB regulatory 
activity [46-48] which in addition to the culture conditions could 
impart differences on the expression and repertoire of binding proteins 
between these strains. Increased adhesion to fibronectin-coated or 
fibrinogen-coated surfaces was demonstrated in S. aureus BB255 (σB-
deficient, rsbU mutation) after complementation with rsbU and in a 
σB-overproducing derivative strain [51]. 
rIsdA antibody inhibition of bacterial binding
Figure 9 shows the adherence assay results for S. aureus SH1000 
and SRC005 after exposure to antiserum (raised against rIsdA) and 
plasma-conditioned steel coupons. Bacterial adherence to a plasma-
conditioning film without antiserum exposure was significantly greater 
for IsdA-deficient S. aureus SRC005 (average increase of +19.9% 
p<0.049, Figure 9A) than that observed for S. aureus SH1000. In the 
complete test system, as observed with S. aureus 8325-4, exposure to 
pre-immune serum significantly promoted the adhesion of S. aureus 
SH1000 compared to adhesion without antiserum exposure (+65.1% 
p<0.003, Figure 9A), whereas no effect was observed on S. aureus 
SRC005 adhesion under the same conditions. Previous research 
has shown a significant role of IsdA in the promotion of heme-iron 
scavenging from host haemoglobin in the pathogenesis of infection 
[39]. Taken together, the results suggest that in the presence of unbound 
serum constituents, IsdA is a potent adhesin and IsdA-mediated 
bacterial adherence to plasma-conditioned biomaterial is significantly 
promoted (p<0.02, SH1000 vs. SRC005, Figure 9A). 
Post-immune serum exposure significantly increased adhesion 
of both strains when compared to pre-immune serum exposure, and 
the level of promotion with S. aureus SH1000 was significantly greater 
than SRC005 (SH1000; +68.1% p<0.02, SRC005; +61.1% p<0.0001, 
Figure 9B; p<0.02, SH1000 vs. SRC005, Figure 9A). The data suggest 
partial involvement of IsdA, however the results with the post-immune 
serum are paramount for indicating the efficacy of any adhesion-
inhibitory antibody that may have been raised against rIsdA; as an 
inhibitory effect must be observed in the presence of other potential in 
vivo interactions and other staphylococcal binding ligands. Opposing 
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Figure 7: Bacterial cell clumping assay.
A: standardised suspensions of S. aureus SH1000 and SRC005 cultured in 
iron-depleted or iron-replenished CL medium (CL, CLFeCl3) were assayed 
for the ability of cell surface–exposed IsdA to enhance cell clumping in the 
presence of purified human fibrinogen. Clumping titers were recorded as the 
lowest fibrinogen concentration at which clumping remained visible. The box 
and whisker plots show the median line, the 75th and 25th percentiles (box) and 
the data range (whisker). Outlier values (circle symbols) fall 1.5-3 box lengths 
from the 75th/25th percentile, and extreme values (square symbols) fall >3 box 
lengths from the 75th/25th percentile. B: example images of bacterial clumping 
in decreasing fibrinogen concentrations and under control conditions. 
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results were observed after exposure to the purified IgG fraction of the 
post-immune serum. A highly significant reduction of adhesion was 
observed with S. aureus SH1000 compared to exposure to pre-immune 
serum (−57.9% p<0.0001, Figure 9B) and compared to un-purified 
post-immune serum (−126.0% p<0.0001, Figure 9B). Whereas purified 
IgG was shown to significantly promote the adherence of S. aureus 
SRC005 compared to pre-immune serum exposure (+52.6% p<0.0001, 
Figure 9B) and this promotion was equivalent to that observed after 
exposure to un-purified post-immune serum for this strain. As the 
two strains differ only in expression of IsdA, the data suggest that the 
reduced adhesion observed with S. aureus SH1000 could be related to 
IsdA-specific adhesion-inhibitory IgG. Although not fully elucidated 
in the current study, if protein A or non-rIsdA specific IgG were 
involved, similar and not opposing results would be expected. Taken 
together, although IsdA–inhibitory IgG may be present the efficacy 
of inhibitory activity appears insufficient to overcome other available 
adhesive interactions when bacteria are exposed to the full complement 
of serum constituents. 
Adhesion of both strains to un-conditioned steel was significantly 
reduced without exposure to antiserum (S. aureus SH1000; −41% 
p<0.0001, S. aureus SRC005; −36.3% p<0.0001). Yet the same trend 
that was observed in the presence of a plasma-conditioning film of a 
significantly higher level of adhesion with S. aureus SRC005 compared 
to S. aureus SH1000 was also observed (+4.7% p<0.001). Although 
formal conclusions cannot be drawn from the current assay, as the two 
strains differ only by presence and absence of IsdA, the results were 
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Figure 8: Standard Curves.
A. Replication phase standard curves. S. aureus SH1000 and S. aureus 
SRC005 cultured in TSB, iron-limited, or iron replenished CL medium (CL, 
CL FeCl3) with incorporated erythromycin for culture of S. aureus SRC005. 
Assays were performed in triplicate and the mean absorbance at 490 nm 
(A490) with the standard error plotted against culture time. B. Viable cell 
number standard curves. Cell density (CFU) and ATP-bioluminescence 
emitted from standardised cultures of S. aureus SH1000 in TSB, CL, or CL 
FeCl3 medium. Assays were performed in triplicate and the mean relative light 
units (RLU) at 595 nm (A595) with standard error plotted against average CFU 
(error bars are shown in black on all graphs, but are difficult to see in some 
cases on account of the errors being small).
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Figure 9: ATP-bioluminescent adhesion assays with rIsdA antiserum.
A. Adherence of standardised cultures of S. aureus SH1000 and SRC005 
(IsdA-deficient mutant) to rabbit plasma-conditioned stainless steel coupons, 
with or without prior antiserum exposure (working titre of 1000, controls sterile 
deionised H2O). B. Normalised mean adherence change expressed as a 
percentage of the adherence in presence of pre-immune serum to plasma-
conditioned stainless steel coupons for S. aureus SH1000 and SRC005 with 
exposure to rIsdA post-immune or purified IgG post-immune serum. All results 
were statistically significantly different to pre-immune serum exposure. In all 
cases adherence was quantified by ATP-bioluminescence and culture. Assays 
were performed in triplicate and values represent the mean adherent CFU ml-1 
or mean % adherent CFU ml-1 with standard error of pooled data (n>100 per 
parameter, error bars are shown in black). Sample means were compared by 
un-paired t-test adjusted for equal or unequal sample variances, significance 
level was p<0.05.
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possibly related to absence of IsdA allowing other bacterial cell surface 
interactions to preside. A general reduction in adhesion of both strains 
to unconditioned biomaterial may be related to the binding protein 
repertoire of these strains. However during this study, only IsdA 
presence was determined. The level of adhesion of S. aureus SH1000 
and SRC005 to un-conditioned steel was not significantly affected by 
exposure to any antiserum. Adhesion in the presence of pre-immune 
serum, post-immune serum and IgG-purified post-immune serum 
was equivalent to that observed without antiserum exposure, and 
equivalent to each parameter, suggesting that the results observed in 
the presence of a plasma-conditioning film are related to the presence 
of deposited plasma constituents. 
Conclusion
This study assessed the ability of antibody raised against rFnBP-A 
and rIsdA to inhibit S. aureus adhesion to plasma-conditioned 
biomaterial in vitro. Significant inhibitory activity was observed with 
rFnBP hyperimmune serum against homologous and heterologous S. 
aureus regardless of virulence; significant equivalent inhibition was 
observed with the MRSA arthroplasty isolate. Inhibitory responses 
appeared to be specifically related to rFnBP-A immunization and 
particularly to the generation of anti-rFnBP-A adhesion-inhibitory 
IgG. As evidenced by the observation of inhibitory responses against 
FnBP-expressing strains only; in the presence of a plasma-conditioning 
film (fibronectin presence); with purified IgG fractions of post-immune 
serum; as well as opposite promotion of adhesion with an FnBP-
deficient mutant strain; and inhibition did not involve protein A or 
non-FnBP / sham IgG. The findings clearly emphasize the potential of 
S. aureus rFnBP-A D-domain as an important candidate for a multi-
component vaccine to prevent S. aureus implant infections.
A significant inhibitory response was also observed with anti-
rIsdA IgG against homologous S. aureus and appeared to be specific 
as evidenced by the inhibition against IsdA-expressing strains only; 
in the presence of a plasma-conditioning film (fibrinogen/fibronectin 
presence); as well as opposite promotion of adhesion with an IsdA-
deficient mutant strain. However, this inhibitory response was not 
retained in the complete test system where bacteria were exposed to 
the full complement of serum constituents. Full rIsdA was used in this 
study and it is possible that use of the NEAT domain of this protein 
may lead to a more specific binding spectrum of elicited antibody and 
increased inhibitory activity due to a reduction in immunological 
epitopes not responsible for ligand binding. IsdA should also be 
investigated for other aspects of implant infection establishment and 
related protective mechanisms given that there have been conflicting 
reports as to whether rIsdA elicited antibody can promote complement-
dependent opsonophagocytic clearance of staphylococci [38,39] and 
more recently anti-rIsdA antibody has been shown to interfere with 
staphylococcal heme-iron scavenging mechanisms [39]. 
A multi-component vaccine against staphylococcal implant 
infection would require elements that elicit cumulative inhibitory 
responses through multiple independent routes such as adhesion 
inhibition, biofilm inhibition and regulatory interference. As described 
in this study there is enormous potential to utilise binding proteins 
to target general bacterial adhesion, further binding proteins that 
may have direct involvement at the implant interface include bone 
sialoprotein binding protein and the serine-aspartate repeat (Sdr) 
proteins, which may impart enhanced inhibitory activity. Utilizing 
intercellular adhesins (ica locus) to target biofilm formation could 
potentially provide cross-inhibitory protection against other major 
causative organisms such as S. epidermidis. A concept that could also 
be incorporated into consideration of the type of adjuvant, for example 
cell wall fatty acid composition of particular Propionibacterium acnes 
strains show similar immuno-stimulatory properties to M. tuberculosis 
[52,53] and was previously shown to stimulate TH1 cell-mediated 
immunity in leukaemia patients [54,55]. As P. acnes is thought to be 
a largely under-estimated cause of orthopaedic implant infections, 
incorporating this organism as an adjuvant is an attractive concept, 
with added potential benefit of extending vaccine spectrum to target 
P. acnes. 
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